Skip to main content

Advanced Biomed Inc.

corporate_fare Company Profile

Advanced Biomed Inc.

ADVB·NASDAQ·Industrial Applications And Services·CIK 0001941029

Advanced Biomed Inc. is a holding company incorporated in the State of Nevada that develops and operates an enterprise AI financial verification platform. In April 2026, Advanced Biomed Inc. acquired 100% of the equity interests of Acellent Technologies (Hong Kong) Co. Limited ("Acellent"). Acellent develops and operates the FinTruth Financial Verification Agent Platform ("FinTruth"), which is designed to compare and verify financial analysis and AI-generated financial content against underlying source documents and financial rules, producing source-traceable and auditable results. In December 2025 and June 2026, Advanced Biomed Inc. sold Advanced Biomed HK (together with its subsidiary, Shanghai Sglcell) and Advanced Biomed Taiwan, respectively. These transactions disposed of the company's biomedical operations, and Advanced Biomed Inc. has since fully shifted its focus towards developing its AI application through FinTruth. Prior to this shift, Advanced Biomed Inc. focused on developing lab devices and chemicals for finding and studying cancer cells in a patient's blood, with the goal of helping doctors detect and monitor cancer through blood tests. Its products included A+Pre, a device for preparing blood samples; the AC-1000, a device for separating cancer cells; the A+SCDrop, a device for isolating individual cells; and the A+CellScan, a device for staining and automatically counting cancer cells. The company also developed dye kits for identifying different types of cancer cells. The A+Pre and AC-1000 devices were the only products not awaiting regulatory approval from the PRC government. As of the date of this Report, Advanced Biomed Inc. has terminated its biomedical business and stopped all research, product development, regulatory approval efforts, manufacturing, and sales activities related to its lab devices, operating chips, and lab chemicals for cancer research.

Advanced Biomed Inc. (NASDAQ:ADVB) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 22 items for ADVB at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Advanced Biomed Inc. Receives Nasdaq Delisting Notice, Files Appeal
  • Advanced Biomed Inc. Approves Reverse Stock Split to Maintain Nasdaq Listing

Financial Snapshot

Fiscal year ended June 30, 2026
Revenue
127.64K
Net Income
6.68M
Diluted EPS
5.33
Op. Cash Flow
-1.95M
Operating Income
-6.23M
Cash & Equivalents
385.54K
Debt / Equity
0.00×
Net Margin
52.31×
Shares Outstanding
1.65M sh
Source: 10-K · filed 2026-10-13 · accession 0001213900-26-109029
$1.67 +1.45% today
52-week range · as of 2026-11-20 $1.58 – $24.23
Market cap
$2.73M
Volume
16.7K (0.2× avg)
3-mo avg 68K
Live data · 2026-11-22 00:03 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ADVB - Filings & News (Page 2)

ADVB
Jan 21, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.3332
Real-time Price: $1.67 info
Change: Reverse Stock Split info
Market Cap: $2.726M info
ADVB
Jan 12, 2026, 4:00 PM EST
Filing Type: PRE 14C
Importance Score:
8
Price at Filing: $0.3352
Real-time Price: $1.67 info
Change: Reverse Stock Split info
Market Cap: $2.726M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets